Evolving Approaches to Vasomotor Symptoms in Menopause - Episode 8

Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women With Breast Cancer Receiving Endocrine Therapy

November 26, 2025

Pauline Maki, PhD, Diana Bitner, MD, MSCP, FACOG, Tara K. Iyer, MD, Barbara Dehn, RN, MS, NP, FAANP, NCMP

Panelists discuss how elinzanetant offers a safe, effective nonhormonal option for managing VMS in women receiving endocrine therapy for breast cancer.

EP. 1: Impact of Vasomotor Symptoms on Patient Quality of Life

EP. 2: Pathophysiology of Vasomotor Symptoms in Menopause

EP. 3: Unmet Needs in Managing Vasomotor Symptoms in Menopause

EP. 4: NK Receptor Antagonism as Therapeutic Strategy for Vasomotor Symptoms

EP. 5: Managing Vasomotor Symptoms With NK3 Receptor Antagonism

EP. 6: Dual NK3/NK1 Receptor Antagonism for Vasomotor Symptoms

EP. 7: Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause

Now Viewing

EP. 8: Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Women With Breast Cancer Receiving Endocrine Therapy

Managing vasomotor symptoms (VMS) in women undergoing endocrine therapy poses unique challenges due to contraindications for hormone use. The OASIS-4 trial explored elinzanetant’s role in this population, offering promising results for symptom control without hormonal interference.

Panelists note that these patients often experience more severe and prolonged VMS due to estrogen suppression. Elinzanetant provided clinically meaningful reductions in symptom burden, improving quality of life and treatment adherence without compromising cancer therapy outcomes.

This represents a crucial advance in supportive care for oncology patients, addressing both physical comfort and emotional resilience during cancer treatment.